RMS is a rare and malignant type of tumor which can arise from skeletal muscles, tendons, or connective tissues. People suffering with RMS may experience different signs and symptoms, some of which may not be seen until the tumor becomes large. The most common symptoms observed in 50% of the children diagnosed with this disease include tumor that can be seen, bleeding from the vagina, nose, throat or rectum (may occur if the location of the tumor is in these areas), numbness, pain or tingling if the tumor affects nerve areas, and drooping of eyelids (may indicate a tumor behind the eye).
RMS THERAPEUTICS UNDER DEVELOPMENT (2018)
Most of the drug candidates under development for the treatment of RMS are small molecules, and they are being used in the formation of combination therapies. These combination therapies are mostly cost-effective, help to ameliorate patient’s compliance, and are easy to manufacture as well as facile to perform quantitative and qualitative testing. The development of such combination therapies is driving the growth of the RMS therapeutics pipeline. Another factor supporting the growth of RMS therapeutics pipeline is the advancement in technologies used for the development of therapeutics.
After thorough study, it has been observed that a number of patent approvals are being procured by most of the companies for drug candidates for the treatment of RMS. This is expected to lead to more certainty of drug approvals for the treatment of RMS in coming years, supported with positive clinical results. As of March 2018, the RMS therapeutics pipeline comprises of 18 drug candidates in different stages of development.
Some of the key players involved in the development of RMS therapeutics include F. Hoffmann-La Roche Ltd., Epizyme Inc. and Novartis AG.